Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan

Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan

Shots:

  • Eidos to receive $25M upfront, $25 equity investment at a premium to the market price upon deal execution, milestone and royalties. Alexion to get an exclusive license to develop & commercialize AG10 in Japan
  • The focus of the agreement is to expand Alexion’s amyloidosis portfolio with the addition of Eidos’ AG10 for patients with transthyretin amyloidosis (ATTR)
  • AG10 (PO) is an investigational therapy to stabilize tetrameric transthyretin, currently being evaluated in P-III study in the US and EU for ATTR cardiomyopathy and demonstrated 90% TTR stabilization @28days in its P-II study. Eidos plans to initiate P-III study of AG10 for ATTR polyneuropathy

Click here to­ read full press release/ article | Ref: Alexion | Image: Twipu